The Nasdaq-listed biotech said the July 20, 2026 package includes options for 7,000 shares at $11.76 and 3,500 restricted stock units under its 2026 inducement plan.
Atrium Therapeutics said it granted employment inducement awards on July 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The package includes non-qualified stock options to buy 7,000 common shares at an exercise price of $11.76 per share, matching the Nasdaq closing price on the grant date, and 3,500 restricted stock units. The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting in 36 substantially equal monthly installments thereafter, while the restricted stock units vest 25% on the first anniversary and the balance in three substantially equal annual installments, in each case subject to continued service. The awards were granted outside the company’s stockholder-approved equity plans and were approved by the Board’s Human Capital Management Committee under Nasdaq Listing Rule 5635(c)(4), which allows inducement grants for new hires.